Another European Study Finds SB4 Tolerated by Most Patients
The study follows others that have found that SB4 works well for the majority of patients who switched from the originator etanercept, Enbrel.
2 Studies Report on Biosimilar Adalimumab Hulio
Two studies recently reported on Hulio, the adalimumab biosimilar marketed and developed by Mylan and its partner Fujifilm Kyowa Kirin Biologics.
2 Commerce Drive Cranbury, NJ 08512